Rapport Therapeutics, Inc. (RAPP) Discusses Phase II Bipolar Mania Trial Results and Business Update TranscriptSeeking Alpha · 4 days ago
Why Is Rapport Therapeutics Stock Trading Higher Today?Benzinga · 4 days ago
Inside the $1 Billion Blockbuster Opportunity That Has Rapport Therapeutics Stock SurgingBarrons · 4 days ago
Rapport Therapeutics Announces Positive Topline Results from its Phase 2 Trial of RAP-219 for the Treatment of Bipolar ManiaGlobeNewsWire · 4 days ago
Rapport: Bipolar Mania Readout May Distort True Value Of Anti-Seizure Med - Rating UpgradeSeeking Alpha · Sep 24, 2026
Rapport Therapeutics, Inc. (RAPP) Discusses RAP-219 Phase II Trial and Unmet Needs in Bipolar Mania TranscriptSeeking Alpha · Sep 22, 2026Rapport Therapeutics, Inc. functions as a clinical-phase biopharmaceutical enterprise, concentrating its efforts on discovering and developing innovative small-molecule therapeutics for individuals living with central nervous system (CNS) disorders. Its flagship product candidate, RAP-219, is an experimental small molecule precisely designed to inhibit TARPy8-containing AMPARs with exceptional potency (picomolar affinity). This promising compound aims to treat focal epilepsy and a range of other neurological conditions, including peripheral neuropathic pain and bipolar disorder.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 5, 2026 | -$0.96 | -$1.19 | Miss |
| May 7, 2026 | -$0.56 | -$0.42 | Beat |
| Mar 10, 2026 | -$0.65 | -$0.72 | Miss |
| Nov 6, 2025 | -$0.77 | -$0.71 | Beat |
| Aug 7, 2025 | -$0.87 | -$0.75 | Beat |
| May 8, 2025 | -$0.77 | -$0.68 | Beat |